nasopharyngeal carcinoma
Conditions
Interventions
before radiotherapy group:Nil
after the confirmed NPC patients received radiotherapy group:Nil
Control group:Nil
Sponsors
Shenzhen Hospital of the University of Hong Kong
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The first group of patients (before radiotherapy) is included in the standard: 1. Initially diagnosed patients with pathologically confirmed nasopharyngeal squamous carcinoma or adenocarcinoma and to be treated with radiotherapy; no intracranial invasion of nasopharyngeal carcinoma; no intracranial tumor and vascular lesions; no heart disease and diabetes; no obvious abnormal signal in the intracranial with conventional MR plain scan and enhanced scan sequence; 2. Aged >=18 years old patients; 3. It is generally in good condition, can cooperate with the examination, and has good liver and kidney functions: serum bilirubin =50ml/min; 4. Provide informed consent. The criteria of the second group (after the confirmed NPC patients received radiotherapy) is as follows: 1. For the patients with nasopharyngeal carcinoma or adenocarcinoma confirmed by pathology, the tumor stage matched with that of the first group. After the diagnosis, all patients received three-dimensional conformal or intensity-modulated radiotherapy in our hospital (the total dose was 66-74 Gy, and the number of divisions was 30-35). There was no intracranial invasion of NPC, no intracranial tumor and vascular lesions, no heart disease and diabetes, and no obvious abnormal signal in conventional MR plain scan and enhanced scan sequence; 2. Aged >=18 years old; 3. It is generally in good condition, can cooperate with the examination, and has good liver and kidney functions: serum bilirubin =50ml / min; 4. Provide informed consent. Criteria for the third group of cases (control group): 1. The normal people matched with the first group's age, gender and education level as the control. MRI scan confirmed that there was no tumor and vascular lesions in the brain; there was no heart disease and diabetes; there was no obvious abnormal signal in the conventional MR plain scan and enhanced scan sequence; 2. Patients over 18 years old; 3. It is generally in good condition, can cooperate with the examination, and has good liver and kidney functions: serum bilirubin =50ml / min; 4. Patients with informed consent.
Exclusion criteria
Exclusion criteria: 1. False admission and false entry; 2. Those who do not conform to the experimental scheme or violate the experimental scheme; 3. Subjects with claustrophobia who could not be examined by MRI; 4. Subjects participating in other clinical trials or subjects participating in other clinical trials within 30 days; 5. Subjects with serious heart, lung, liver, kidney and other diseases, limited speech or hand movement, serious hearing or vision disorders, brain atrophy reported in the Journal of imaging, other brain diseases in the history, dependence on psychoactive substances or other mental diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MR signal; | — |
Countries
China
Contacts
Public ContactLiang Chunyu
Shenzhen Hospital of the University of Hong Kong
Outcome results
None listed